研究单位：[1]Sinocelltech Ltd.[2]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,Beijing,China[3]Xuanwu Hospital, Capital Medical University,Beijing,China[4]Jilin Provincial People''s Hospital,Changchun,China[5]Guangdong Provincial People''s Hospital,Guangzhou,China[6]Zhejiang Provincial People''s Hospital,Hangzhou,China[7]The First People''s Hospital of Jiujiang City,Jiujiang,China[8]The First Affiliated Hospital of Kunming Medical University,Kunming,China[9]Linfen Central Hospital,Linfen,China[10]Mianyang Central Hospital,Mianyang,China[11]The First Affiliated Hospital of Nanchang University,Nanchang,China[12]Pingxiang People''s Hospital,Pingxiang,China[13]Shanxi Bethune Hospital,Taiyuan,China[14]The First Affiliated Hospital of Xiamen University,Xiamen,China[15]Xinxiang Central Hospital,Xinxiang,China
研究目的：
This study is a multicenter Phase Ib/II clinical trial aimed at evaluating the safety, tolerability and efficacy of SCTB35 in patients with systemic lupus erythematosus (SLE).
